See every side of every news story

Published 17 days ago • loading... • Updated 17 days ago

FPSA - Novel Salmonella Vaccine Shows Promise in Clinical Trial

Summary by FPSA

The Trivalent Salmonella Conjugate Vaccine (TSCV), which simultaneously addresses typhoid fever and foodborne illness caused by non-typhoidal Salmonella enterica, elicited strong immune response in 100 percent of participants in the randomized, placebo-controlled clinical trial. Read MoreThe post Novel Salmonella Vaccine Shows Promise in Clinical Trial appeared first on FPSA.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

FPSA - Novel Salmonella Vaccine Shows Promise in Clinical Trial

The Trivalent Salmonella Conjugate Vaccine (TSCV), which simultaneously addresses typhoid fever and foodborne illness caused by non-typhoidal Salmonella enterica, elicited strong immune response in 100 percent of participants in the randomized, placebo-controlled clinical trial. Read MoreThe post Novel Salmonella Vaccine Shows Promise in Clinical Trial appeared first on FPSA.

17 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated17 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

FPSA broke the news in 17 days ago on Thursday, October 9, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics